Champions Oncology, Inc. (CSBR) — Analyst outlook / Analyst consensus target is. Based on 7 analyst ratings, the consensus is bullish — 5 Buy, 2 Hold.
The consensus price target is $12.00, representing an upside of 109.4% from the current price $5.73.
Analysts estimate Earnings Per Share (EPS) of $-0.63 and revenue of $0.05B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-0.54 vs est $-0.63 (beat +14.3%). 2025: actual $0.34 vs est $0.30 (beat +13.3%). Analyst accuracy: 86%.
CSBR Stock — 12-Month Price Forecast
$12.00
▲ +109.42% Upside
Average Price Target
Based on 7 Wall Street analysts offering 12-month price targets for Champions Oncology, Inc., the price target is $12.00.
The average price target represents a +109.42% change from the last price of $5.73.
CSBR Analyst Ratings
Buy
Based on 7 analysts giving stock ratings to Champions Oncology, Inc. in the past 3 months
EPS Estimates — CSBR
86%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$0.54
vs Est –$0.63
▲ 16.7% off
2025
Actual $0.34
vs Est $0.30
▲ 11.8% off
Profitability Outlook
Company has mixed profitability — some years profitable, some at a loss. EPS trend is improving.
Revenue Estimates — CSBR
98%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.050B
vs Est $0.049B
▲ 2.7% off
2025
Actual $0.057B
vs Est $0.057B
▲ 0.6% off
Revenue Trend
Moderate revenue growth trend. Analysts forecast revenue contraction ahead.
